Showing 2421-2430 of 4063 results for "".
- Johnson & Johnson Marks 100,000 US Implants of Tecnis Odyssey IOL; Showcases Innovations at AAO 2025https://modernod.com/news/johnson-johnson-marks-100000-us-implants-of-tecnis-odyssey-iol-and-showcases-innovations-at-aao-2025/2484177/Johnson & Johnson announced that its Tecnis Odyssey IOL has now been implanted in 100,000 eyes since its 2024 launch. The company will highlight this milestone alongside new data presentations and technology showcases
- Glaukos to Highlight Innovations at the 2025 American Academy of Ophthalmology Annual Meetinghttps://modernod.com/news/glaukos-to-highlight-innovations-at-the-2025-american-academy-of-ophthalmology-annual-meeting/2484175/Glaukos announced that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held October 18-20, 2025, in Orlando. Glaukos will be exhibiting onsite at booth #2921.
- Alcon Showcases Breakthrough Innovations and New Clinical Data at AAO 2025https://modernod.com/news/alcon-showcases-breakthrough-innovations-and-new-clinical-data-at-aao-2025/2484167/Alcon will highlight a lineup of new technologies and clinical data at the 2025 American Academy of Ophthalmology (AAO) annual meeting, October 18–20, in Orlando. At booth #2120, ophthalmologists, surgical staff,
- Zeiss to Showcase Advancements in Ophthalmic Visualization and Digital Workflow at AAO 2025https://modernod.com/news/zeiss-to-showcase-advancements-in-ophthalmic-visualization-and-digital-workflow-at-aao-2025/2484161/Zeiss Medical Technology will present its latest innovations in ophthalmic visualization, diagnostics, and digital workflow solutions at the American Academy of Ophthalmology (AAO) annual meeting, taking place October 18–20, 2025, in Orlando.
- Kala Halts Development of Investigational PCED Eye Drop After Phase 2b Trial Fails to Meet Endpointshttps://modernod.com/news/kala-halts-development-of-investigational-pced-eye-drop-after-phase-2b-trial-fails-to-meet-endpoints/2484150/Kala Bio said it is ceasing development of KPI-012 and its mesenchymal stem cell secretome (MSC-S) platform after its phase 2b trial evaluating KPI-012 in persistent corneal epithelial defect (PCED) did not meet its primary or secondary efficacy endpoints.
- The Vision Council Releases Focused inSights 2025: Smart Eyewearhttps://modernod.com/news/the-vision-council-releases-focused-insights-2025-smart-eyewear/2484143/The Vision Council announced the release of 'Focused inSights 2025: Smart Eyewear,' a consumer research report that highlights growing interest and evolving attitudes toward the developing smart eyewear category. Drawing on survey responses from more than 4
- PulseSight Therapeutics to Present New Data on Iron Dysregulation and Ferroptosis in AMD at Euretina 2025https://modernod.com/news/pulsesight-therapeutics-to-present-new-data-on-iron-dysregulation-and-ferroptosis-in-amd-at-euretina-2025/2484133/PulseSight Therapeutics announced that its Chief Scientific Officer, Thierry Bordet, PhD, will present new clinical and preclinical findings on the role of iron dysregulation and ferroptosis in age-related macular degeneration (AMD) at the 25th Euretina Congre
- Nanoscope to Present Long-Term Data for MCO-010 in RP at Euretina and Retina Society 2025https://modernod.com/news/nanoscope-to-present-long-term-data-for-mco-010-in-rp-at-euretina-and-retina-society-2025/2484129/Nanoscope Therapeutics announced it will present new long-term data from its RESTORE follow-up study, REMAIN, at two major international meetings: the 2025 Euretina Congress in Paris and the 2025 Retina Society Annual Scientific Meeting in Chicago.
- FDA Grants Fast Track Designation to Aldeyra’s ADX-2191 for Retinitis Pigmentosahttps://modernod.com/news/fda-grants-fast-track-designation-to-aldeyras-adx-2191-for-retinitis-pigmentosa/2484124/The FDA has granted Fast Track Designation for Aldeyra Therapeutics' ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigmentosa (RP). The FDA’s Fast Track progra
- PolyActiva Initiates US Phase 2b Clinical Trial of PA5108 Biodegradable Ocular Implant for Glaucoma and OHThttps://modernod.com/news/polyactiva-enrolls-first-patient-in-us-phase-2b-clinical-trial-of-its-ocular-micro-implant-for-glaucoma-and-ocular-hypertension/2482925/PolyActiva announced the enrollment of the first US patient in its phase 2b clinical trial evaluating PA5108, a novel intracameral, biodegradable micro implant designed to provide sustained IOP reduction in patients with primary open-angle glaucoma (POAG)